Los Angeles Times - February 28, 2009
Mary Engel
A study published Wednesday in the journal Nature confirms that dizzying pace of evolution on a global scale.
"It's very clear there's a battle going on between humans and this virus, and the virus is evolving to become unrecognized by the immune system," said Dr. Bruce Walker, one of the researchers and director of the Ragon Institute, at Massachusetts General Hospital in Boston. "It does make clear what a huge challenge making a vaccine is."
HIV evolves to escape the immune system, much in the same way that bacteria mutate under pressure by antibiotics, Walker said.
Researchers looked at HIV genetic sequences in the United Kingdom, South Africa, Botswana, Australia, Canada and Japan to see how they evolved in response to a key set of molecules in the human immune system, called human leukocyte antigens. These molecules direct the immune system to recognize and kill HIV and other infectious diseases.
Genes that encode human leukocyte antigens vary among humans, and even small differences can dramatically affect a person's response to HIV infection. For example, an adult infected with HIV will survive on average about 10 years without anti-HIV drugs before developing acquired immune deficiency syndrome. But some people will progress to AIDS within a year, and others can survive without treatment for 20 years.
The study published online Wednesday found that mutations occurred not just in individuals but on a population level. That is, if a particular genetic immune sequence was common in a population, the HIV mutation that evolved to escape it became the most common strain of HIV, even in those without that particular human leukocyte antigen gene.
"What this study does is give an explanation for why there are different HIV strains in different parts of the world," Walker said. "The genetic makeup of people in different regions is influencing the virus in specific ways."
This would appear to be bad news for the director of the newly opened Ragon Institute of MGH, MIT and Harvard, which was founded to develop vaccines for HIV and other infectious diseases.
But Walker saw the results as hopeful. He said that mutations can actually make the virus less fit -- that is, unable to replicate as quickly or do as much damage. His challenge is to find what kind of pressure results in this kind of mutation.
Researchers from the Ragon Institute, Oxford University in England, Kumamoto University in Japan, and Royal Perth Hospital and Murdoch University in Australia analyzed the genetic sequences of HIV and human leukocyte antigen genes in 2,800 people total.
mary.engel@latimes.com
090228
LT090208
Copyright © 2009 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .